Telomir Pharmaceuticals, Inc. Common StockTELONASDAQ
Loading
R&D Expenses Over TimeStrong
Percentile Rank100
3Y CAGR+43.0%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
+43.0%/yr
Annual compound
Percentile
P100
Near historical high
vs 3Y Ago
2.9x
Strong expansion
Streak
4 yr
Consecutive growthStrong
PeriodValueYoY Change
2025$2.44M+9.0%
2024$2.24M+42.0%
2023$1.57M+88.9%
2022$833206.00+558.7%
2021$126492.00-